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Abstract Raised intracranial pressure is a common problem
in a variety of neurosurgical conditions including traumatic
brain injury, hydrocephalus and intracranial haemorrhage.
The clinical management of these patients is guided by a va-
riety of haemodynamic, biochemical and clinical factors.
However to date there is no single parameter that is used to
guide clinical management of patients with raised intracranial
pressure (ICP). However, the role of ICP indices, specifically
the mean pulse amplitude (AMP) and RAP index [correlation
coefficient (R) between AMP amplitude (A) and mean ICP
pressure (P); index of compensatory reserve], as an indicator
of true ICP has been investigated. Whilst the RAP index has
been used both as a descriptor of neurological deterioration in
TBI patients and as a way of characterising the compensatory
reserve in hydrocephalus, more recent studies have highlight-
ed the limitation of the RAP index due to the influence that
baseline effect errors have on the mean ICP, which is used in
the calculation of the RAP index. These studies have sug-
gested that the ICP mean pulse amplitude may be a more
accurate marker of true intracranial pressure due to the fact
that it is uninfluenced by the mean ICP and, therefore, the
AMP may be a more reliable marker than the RAP index for
guiding the clinical management of patients with raised ICP.
Although further investigation needs to be undertaken in order
to fully assess the role of ICP indices in guiding the clinical
management of patients with raised ICP, the studies
undertaken to date provide an insight into the potential role of
ICP indices to treat raised ICP proactively rather than reactively
and therefore help prevent or minimise secondary brain injury.
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Introduction
The accurate measurement of dynamic intracranial pressure is
complex. Although the measurement of ICP is an important
factor in determining both the clinical management and out-
come of patients with several neurosurgical conditions, recent
studies have looked at the use of measuring the compensatory
reserve as a possible predictor of clinical outcome and how it
could be used to guide clinical management. Czosnyka et al.
designed a coefficient between the mean intracranial pressure
and the ICP mean pulse amplitude, the RAP index, as a po-
tential descriptor of neurological deterioration in traumatic
brain injury (TBI) patients [1]. Since this publication it has
also been used to characterise the compensatory reserve in
patients with hydrocephalus [2]. More recent studies have
researched the use of the RAP index as a possible marker to
guide clinical management in patients with raised ICP. This
has included analysing the effects of baseline effect errors on
both the RAP index as well as the ICP wave parameters,
including the ICP mean pulse amplitude (AMP) [3, 4].
These studies concluded that baseline effect errors may hinder
the use of the RAP index as a marker to guide clinical man-
agement due to their influential effect on the mean ICP,
which is one of two factors used to calculate the RAP
index. Other studies have shown that the AMP, as opposed to
the RAP index, is refractory to these baseline errors and may
provide a more accurate marker to guide clinical management,
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as well as its potential to predict mortality in certain neurosur-
gical events including traumatic brain injury [5].
This review will give an overview of intracranial pressure
including its monitoring and examine the evidence from pre-
vious studies regarding the potential role of both the RAP
index and the AMP as a marker to guide clinical management.
Intracranial pressure
Physiology
Intracranial pressure (ICP) is derived from the circulatory dy-
namics of the CSF and cerebral blood flow that occur within
the rigid intracranial compartment [6]. This relationship forms
the ICP waveform, which consists of a cardiac component,
which involves three peaks, a respiratory component, which
is a reflection of the respiratory cycle on cerebral venous
blood flow, and slow vasogenic waves of ICP, secondary to
autoregulation-derived cyclic fluctuations of arterial blood
volume (Fig. 1). ICP is affected by many factors both within
and outside of the intracranial compartment.
Under normal circumstances ICP is kept within a cer-
tain range primarily with cerebral auto-regulation, which
is itself dependent on cerebrovascular reactivity. The fact
that true ICP is influenced by many factors and has both
inter- and intra-patient variability makes accurate mea-
surement of true ICP difficult. For example, the value of
ICP is affected by age, body posture, time of day as well
as the clinical condition of the patient. However a normal
range of ICP has been established in order to address the
multi-variant nature of ICP, as well as general interven-
tional thresholds for ICP in different neurosurgical
conditions.
Intracranial factors that can affect ICP can be broadly
categorised into three main intracranial areas: disturbances
in the dynamics of CSF; the expansion of intracranial
tissue itself; the expansion of blood volume (Fig. 2).
Disturbances within these intracranial areas can be caused
by several factors including disturbances in the normal
vascular architecture (resulting in either haemorrhage or
mass effect), infection, malignancy (including metastasis)
and trauma.
Extra-cranial factors are diverse and more difficult to
manage from a neurosurgical point of view. For example,
both the intra-thoracic compartment and, to a lesser ex-
tent, the intra-abdominal compartment influence ICP, in
both the acute and chronic setting. In particular, the respi-
ratory system plays a crucial role in the cerebral circula-
tory dynamics. This is evident by the role of ventilation to
help reduce the vasodilatory effects of CO2 in patients
with TBI [7, 8].
Measurement and monitoring
Although understanding the homeostasis of ICP and its rela-
tionship to intracranial events is vital, the accurate measure-
ment of true ICP is crucial in understanding its role in abnor-
mal intracranial physiology and its effect on clinical outcome.
Measuring ICP is conventionally undertaken using either
an intra-parenchymal or intra-ventricular transducer. It has
been hypothesised that measuring intracranial pressure from
a single source is itself a source of inaccuracy due to the
complex three-dimensional pressure gradients that are
established as a result of the complex intracranial architecture
and physiology (Fig. 3). Studies have shown there is regional
cerebral homeostasis as a result of regional effects on vascu-
lature from local factors including metabolic and neural fac-
tors [9]. This local effect on regional vasculature is driven by
cellular events ranging from increased production of waste
products from cellular metabolism to changes in local neuro-
nal activity. The reactivity of cerebral blood flow (CBF) to
metabolic demand is not only rapid but is not always propor-
tional [9]. This regional homeostatic effect has the potential to
be another factor that could affect the true ICP values when
measuring the ICP from a single source. However due to the
invasive nature of ICP monitoring, accurately measuring pan-
cranial ICP using the current invasive methods would be
impractical.
Non-invasive methods of monitoring ICP have been
assessed, including MRI and ultrasonography [10]. In partic-
ular the use of ultrasonography to measure optic nerve sheath
diameter to assess dynamic changes in ICP has shown prom-
ising results [11]. Although no method has currently been
found to be a suitable substitute for the more invasive method
of ICP monitoring [12], further study into its use as a method
of monitoring ICP from a variety of intracranial points would
be useful, in particular, the potential role of using imaging
techniques including fMRI to assess cerebral function and
thereby establish the full relationship between raised ICP
and changes in cerebral function. However the heterogeneity
of cerebral vascular reactivity caused by ischaemia-induced
impairment of cerebrovascular dynamics, including
neurovascular coupling, could potentially hinder the use of
fMRI in accurately assessing cerebral function in conditions
that disrupt the blood-brain barrier such as in TBI.
Intracranial pressure indices
The RAP index
Czosnyka et al. designed an index that is a correlation coeffi-
cient between the mean ICP and the ICP mean wave ampli-
tude (AMP)—the RAP index [correlation coefficient (R) be-
tween AMP amplitude (A) and mean pressure (P); index of
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Fig. 1 An illustration of the ICPwaveform components. a (i) The ICP
waveform showing the cardiac component (W1) and respiratory
component (W2). The cardiac component consists of three peaks: P1
(reflects arterial pulsation), P2 (reflects, to a degree, intracranial
compliance) and P3 (reflects aortic valve closure). The respiratory
component reflects the cerebral venous pulsation generated by the
changes in intra-thoracic pressure that is generated by respiration. a (ii)
An illustration of what the individual ICP wave form peaks represent in
terms of intracranial physiology. The black oscillating arrow represents
arterial pulsations (red area), which subsequently become venous
pulsations (blue area) as cerebral blood travels through the cerebral
vasculature. P1 is the pressure generated in the CSF as a result of the
pressure generated from the arterial pulsation. P2 is the pressure generated
within the CSF as a result of the forces generated from both the pulsatile
blood vessel and the resistance from the intracranial tissue. The higher the
resistance is, the greater the pressure within the CSF and therefore the
greater the P2 wave amplitude. Note the intracranial compliance, and
therefore the value of P2, can be affected by any factor from the
endothelium of the cerebral blood vessel to the intracranial surface of
the skull (represented by P2) Diagram key: 1, skull; 2, dura layer; 3,
arachnoid layer; 4, subarachnoid space containing the cerebrospinal
fluid (represented in green); 5, pia layer; 6, cerebral tissue. b The
individual ICP waveform peaks. Under the normal intracranial
physiological state, P1 > P2 > P3. However when ICP is raised, and there
is reduced intracranial compliance, P1 < P2 > P3. c The slow vasogenic
waves of ICP, secondary to autoregulation-derived cyclic fluctuations of
arterial blood volume. A waves, or plateau waves, always indicate
pathology and signify reduced intracranial compliance. Once they are
present, the patient will likely have neurological deterioration. They
involve a steep rise in ICP from around a normal value to 50 mmHg or
more. They persist for 5-20 min after which there is a sharp decline. B
waves are more subtle than A waves and can indicate several
abnormalities of intracranial homeostasis including being an indicator
of failing intracranial compensation. It is important to note however that
they can also be present in patients with normal ICP. B waves are
rhythmic oscillations with ICP rising in a crescendo manner to levels
20–30 mmHg higher than baseline, with a subsequent sharp decline.
They occur every 1–2 min. Note, Lundberg Awaves and B waves refer
to raises in static (mean ICP) and are not related to the pressure
fluctuations during the cardiac cycle, which is the case for ICP wave
amplitudes
Acta Neurochir (2016) 158:1997–2009 1999
compensatory reserve]. This was first introduced as a potential
descriptor for neurological deterioration in TBI patients. It
was subsequently used to characterise the pressure-volume
compensatory reserve in patients with hydrocephalus. The
RAP index has been shown to be a reliable measure of the
compensatory reserve; however in more chronic states the
cerebrospinal elasticity coefficient (E1) and AMP have been
shown to express the compensatory reserve better [13–16].
This is due to the fact that raised ICP in chronic states, such
as hydrocephalus and intracranial hypertension, is due to
increased cerebral venous outflow or increased resistance to
CSF outflow rather than the exhaustion of the cerebrospinal
compensatory reserve. The RAP index has also been shown to
be an accurate measure of intracranial compliance [17]. In
addition, the RAP index has been used to assess the use of
extra-ventricular devices to investigate the role of cerebral
auto-regulation disturbances in aneurysmal subarachnoid pa-
tients [18].
The numerical value of the RAP index can range from +1
to -1 (Fig. 4). An RAP value of 0 is interpreted as lack of
synchronisation between the changes in AMP and mean
ICP. In terms of the pressure-volume relationship, an increase
in intracranial volume does not result in a rise in ICP.
When the RAP index rises to +1, there is synchronisation
between the rise in AMP and the rise in ICP. In terms of the
pressure-volume relationship, a small rise in intracranial vol-
ume results in a larger rise in ICP.
If the ICP continues to rise, the RAP index value becomes -
1. At this point the AMP has an inverse relationship to ICP—
the AMP decreases as the ICP continues to rise. At this stage
the compensatory reserve is exhausted and cerebral auto-
regulation collapses. It is at this point that cerebral
ischaemia- induced irreversible brain damage will likely occur
and, ultimately, brain herniation. Note however that cerebral
ischaemia will rise in a gradient fashion as the ICP continues
to rise.
More recent studies have researched the potential role of
the RAP index as a marker to guide clinical management [2,
19, 20]. However these studies found that the use of RAP as a
potential marker to guide clinical management may be
Fig. 3 The effect of pressure gradients on ICP monitoring. If the
transducer is placed in the frontal-parietal region, as shown, the effect
of the pressure gradients generated by event 1 (ICP1), for example
cerebellar haematoma within the infra-tentorium, has the potential to be
different from the effect of the pressure gradient that is generated by event
2 (ICP2), for example TBI. The three-dimensional pressure gradients
generated against the cerebral tissue itself is what will ultimately affect
cellular function—the core issue in raised ICP. Note that the cerebral
blood vessels also generate pressure gradients, which are a result of
both cerebral blood flow and cerebral blood volume, and are influenced
by cerebral vascular reactivity. Diagram key: C1, superior sagittal sinus;
C2, inferior sagittal sinus; C3 and C4, transverse sinus, A and B, lateral
ventricles
Fig. 2 Intracranial factors that affect ICP: the Monro-Kellie
Doctrine. Each circle represents one of the three broad intracranial
categories: blood, CSF and brain tissue. If the normal physiological
and/or anatomical state of either one of these categories is altered, and
the compensatory change from the other categories is exhausted, this will
result in an increase in ICP. The overlap of the circles represents how each
category can affect the other (a, b, c). The density of the circles correlates
with the ICP, with * denoting the highest ICP
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hindered by baseline effect errors. In particular it was found
that baseline effect errors had a significant influence on the
mean ICP as to render it an inaccurate reflection of the true
ICP. This in turn influences the RAP index, which is calculat-
ed by correlating slow fluctuations of ICP and pulse
amplitude.
ICP mean pulse amplitude (AMP)
The ICP mean pulse amplitude relates to the pressure fluctu-
ations of the ICP during the cardiac cycle. The AMP increases
as the ICP rises; however once the critical ICP has been
reached there will be subsequent derangement of cerebrovas-
cular reactivity and AMP will decrease.
More studies are beginning to research the use of AMP
both as a more accurate marker of the true ICP, in place of
the mean ICP, as well as a tool to help guide the clinical
management of patients [21, 22]. The influence that baseline
effect errors have been shown to have on the mean ICP has
raised questions as to how accurately the mean ICP value
reflects the true underlying ICP. In particular it has been
shown that AMP can make a useful contribution to the
Fig. 4 The relationship among
the pressure-volume curve,
RAP index and cerebral
auto-regulation.When the RAP
index is close to 0, cerebral
auto-regulation remains intact and
there is good compensatory
reserve. As the ICP continues to
rise and the RAP index
approaches +1, the compensatory
reserve decreases; however
cerebral auto-regulation remains.
When the ICP reaches the critical
value, cerebral auto-regulation is
lost and there is no compensatory
reserve
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diagnosis of hydrocephalus as well as predict a positive out-
come after shunt insertion [23]. However its use as a single
parameter to guide clinical management has not yet been
justified.
Although it has been demonstrated that AMP is refrac-
tory to baseline effect errors, further study into what other
factors could potentially affect AMP, and therefore its
usefulness in clinical management, must be investigated.
This includes investigating the extent to which any factor
influences AMP across the different pathological condi-
tions. For example, studies have shown that AMP is more
dependent on pulse changes in arterial blood volume in
patients with TBI than in those with normal pressure hy-
drocephalus [24].
Further studies have assessed the AMP in relation to
clinical outcome and have shown that a lower AMP is
associated with a better outcome following TBI [25] and
surgery [26].
One proposed advantage of using AMP instead of the RAP
index is its ability to reflect the dynamic nature of true ICP
without influences from static values, which have the potential
to be affected by other dynamic factors such as baseline effect
errors. However one limitation of using the AMP is the ability
of researchers to accurately analyse the multi-variant and dy-
namic nature of the ICP waveform in an objective way.
Studies have looked at more sophisticated algorithms of ob-
jectively analysing ICP wave parameters, including AMP,
with a degree of success.
For example, it has been shown that the time domain
method is superior to the frequency domain method for
ICP waveform analysis since the frequency domain meth-
od can underestimate the AMP in the presence of heart
rate variability or if the waveform has a high harmonic
distortion [27]. Holm et al. [27] showed that the differ-
ence in the AMP calculated from these two methods was
significant, with a difference of ≥2.0 mmHg in more than
half of the 50,978 6-s t ime windows analysed.
Furthermore, this difference will also affect the RAP in-
dex since the AMP is one of its components. Therefore, it
is important that a standard method of analysis for the
AMP is used in order to achieve robust results that can
be accurately interpreted, which is important if both the
RAP index and AMP are to be used to guide clinical
management.
More recent studies have used more sophisticated algo-
rithms to analyse the individual ICP waveform peaks (P1,
P2, P3) with a high degree of accuracy.
However the successful clinical use of such algorithms for
accurate, objective analysis of Lundberg waves, in particular
B waves, has still to be proven [28, 29]. The proactive treat-
ment of raised ICP instead of reactive treatment is one poten-
tial area where ICP waveform parameters, including AMP,
could prove useful [30–32].
Baseline effect errors
Baseline effect errors (BEEs) are spontaneous shifts in base-
line pressure that occur during continuous ICP monitoring.
They were first described by Eide in 2006 [33] when moni-
toring ICP simultaneously from two separate sensors in which
there was a marked difference in mean ICP, combined with
close to identical ICP waveform components such as AMP.
Baseline effect errors can be caused by a variety of factors
ranging from all components of the ICP monitoring system,
including the sensor, cable, display and transducer, to imper-
fect fluid connection caused by debris or air bubbles.
In relation to ICP indices, this is very important since any
ICP index that includes mean ICP in its component will be
affected, including the RAP index. However since the AMP is
included in the RAP index, the effect of BEE is less pro-
nounced in the RAP index than in the mean ICP. Therefore,
any ICP index that is solely based on static pressure measure-
ments can expect to be affected by BEE.
The ability of baseline effect errors to influence the value of
the RAP index, and therefore the true nature of the patients
underlying intracranial compensatory reserve, has the poten-
tial to affect clinical management. It has been shown that
significant differences in the RAP index correspond to the
occurence of BEEs and that the differences are of a magnitude
that could affect patient management [3]. For example, an
inaccurate RAP index could give the clinician a false reflec-
tion of the patient’s underlying intracranial physiological state
and therefore instigate an erroneous change in their manage-
ment that could range from altering doses of certain medica-
tions to undertaking inappropriate surgical intervention.
Baseline effect errors also have the potential to affect cere-
bral perfusion pressure, through the effect it has on intracranial
pressure (since CPP is equal to mean arterial pressure minus
intracranial pressure). For example, if BEEs are caused by an
imperfect fluid connection as a result of debris or air bubbles,
this could result in a fall in CPP if the ICP rises beyond the
limits of cerebral auto-regulation.
Current guidance in the clinical management
of raised ICP
Raised ICP is defined as a sustained ICP of greater than
20 mmHg. However the thresholds for management depend,
in part, on the underlying cause. At present there is no single
parameter that has been proven to be the best marker to guide
the clinical management of raised ICP. Due to the multi-
variant nature of ICP between conditions and between patients
it is doubtful whether it is possible to have one single param-
eter that can successfully guide the clinical management. The
current treatment options for raised ICP range from initial
medical management involving general physiological
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homeostasis to management, which involves more radical in-
terventions including endotracheal intubation, barbiturate co-
ma, and surgical evacuation or decompression. The ultimate
goal of treating raised ICP is to prevent or minimise secondary
brain injury by restoring intracranial homeostasis in order to
reach optimum cerebral function.
Treatment options
General physiological homeostasis
General physiological homeostasis involves controlling sev-
eral parameters, which include blood pressure, serum osmo-
larity, temperature and blood glucose, as well as maintaining
adequate partial arterial pressures of oxygen.
Blood pressure control has an important role in the treat-
ment of raised ICP; however the exact treatment thresholds
required to achieve optimum cerebral function in the setting of
raised ICP remains ambiguous. This is in part due to the fact
that patients with raised ICP often have several contributing
factors. An important consideration in the control of a pa-
tient’s blood pressure within the context of raised ICP is the
fine balance required between under-treatment of hyperten-
sion, and therefore increasing the possibility of haemorrhage
or mass effect, and over-treatment of hypertension, and thus
increasing the risk of ischaemia-induced damage to cerebral
function. One therapy that aims to reduced the risk of
ischaemia-induced cerebral damage is cerebral perfusion pres-
sure (CPP)-guided therapy. This therapy aims tomaintain CPP
greater than 70 mmHg in order to minimise ischaemia, which
is induced by compensatory cerebral vasodilation [34–36].
However CPP-guided therapy is not conclusive as it has been
shown that this approach can cause a rise in ICP [37].
Another approach used to control blood pressure is the
BLund Protocol^ in which a disruption of the blood-brain
barrier is assumed. This places emphasis on reducing the hy-
drostatic forces whilst increasing the osmotic forces to main-
tain fluid within the intravascular compartment and thus pre-
vent vasogenic oedema [38].
In addition to ensuring adequate CPP, oxygen levels must
be adequately maintained, particularly in patients who have
suffered TBI or intracerebral haemorrhage (ICH) in which the
presence of pericapillary oedema may reduce the diffusion
ability of oxygen to cross the blood-brain barrier.
Another important therapeutic target in raised ICP is
glycaemic control. It has been shown in several studies that
hyperglycaemia increases both the morbidity and mortality in
patients with several neurological conditions including ICH
and traumatic brain injury (TBI) [39–42, 43, 44]. Several of the
underlying reasons for this increase in morbidity and mortality
are the widespread detrimental effect that hyperglycaemia has
on the cardiovascular system. However it has also been shown
that hyperglycaemia causes a rise in ICP [45]. In particular, the
breakdown of the blood-brain barrier that occurs in TBI pa-
tients results in the influx of glucose into the cerebral tissue
thereby causing an increase in oedema through osmosis.
Minimising pyrexic episodes in patients with raised ICP is
very important as an increase in temperature results in a rise in
the cerebral metabolic rate, which can precipitate ischaemia
directly, or indirectly through oedema. This is evident by stud-
ies that have shown, through experimental models of brain
injury, the detrimental effect fever has on clinical outcome
[46, 47]. Furthermore, the incidence of fever in patients who
suffer basal ganglionic and lobar ICH, particularly ventricular
haemorrhage, is high. Fever is also an independent predictor
of poor clinical outcome after severe head injury. Therefore
aggressive treatment of fever in patients with raised ICP is
encouraged.
Head of bed elevation
Elevation of the head to 30° improves jugular venous outflow
and reduces ICP. However caution must be used in patients
who are hypovolemic as elevation in these patients could re-
sult in a fall in CPP, which could have significant effects on
cerebral function, depending on the volume and duration of
the drop in CPP.
Analgesia and sedation
Analgesia is important in order to minimise the potential
harmful effect on ICP. Sedation may be used in order to ap-
propriately ventilate patients who are unable to achieve ade-
quate ventilation on their own. However this must be titrated
with care in order to minimise the detrimental effect it may
have on the clinician’s ability to clinically evaluate the patient.
Neuromuscular blockage
Patients who fail to respond to analgesia and sedation, and
who still have intracranial hypertension, may benefit from
neuromuscular blockade as seizure activity causes a rise in
intra-thoracic pressure, which can obstruct cerebral venous
outflow resulting in an increase in ICP. One of the drawbacks
of this therapy is the masking of seizure activity.
Osmotic agents
One of the most important physiological properties that must
be carefully balanced in patients with raised ICP is serum
osmolarity. Both mannitol and hypertonic sodium chloride
are the most common agents used.
Mannitol acts through two mechanisms. First, it increases
intravascular volume and results in a reduction in blood vis-
cosity. The intravascular volume expansion results in an in-
crease in cardiac pre-load and thus an increase in CPP.
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Through cerebral auto-regulation, compensatory cerebral va-
soconstriction occurs, which reduces the ICP. Second, manni-
tol draws water from the extracellular cerebral tissue into the
plasma, thereby reducing cerebral oedema. However if the
blood-brain barrier is disrupted, care must be taken to avoid
worsening any cerebral oedema.
Hypertonic saline (HTS) can be used because of its osmotic
effects as a result of its hypertonicity compared to extracellular
cerebral tissue. However hypertonic saline also has haemody-
namic, vaso-regulatory, immunological and neurochemical ef-
fects [48]. One recent study looked at the difference in cumu-
lative and daily ICP burdens after severe traumatic brain inju-
ry between hypertonic saline and mannitol and found that
HTS was more effective than mannitol when given as a bolus
therapy. However the 2-week mortality rates between the two
were not statistically different [49].
Steroids
The use of steroids in raised ICP is limited to treat vasogenic
oedema where the underlying cause is primary and metastatic
tumours. Steroids have shown no benefit in TBI or spontane-
ous intracerebral haemorrhage [50, 51].
In some studies they have been shown to have a detrimen-
tal effect [52, 53].
Steroids can also be used in CNS infection; however care
should be taken in intracerebral abscesses as they can retard
the encapsulation process, worsen necrosis and reduce the
permeability of antibiotics.
Hyperventilation
The use of CO2 influence on cerebral auto-regulation provides
one of the most effective methods for rapidly lowering ICP.
This is achieved through ventilation, which allows the clini-
cian to lower CO2 levels and induce compensatory cerebral
vasoconstriction and thus reduce the ICP. One caveat to using
this property of CO2 is the ability of the extracellular space of
the brain to accommodate the associated changes in pH, and
thus once CO2 levels begin to normalise a compensatory in-
crease in ICP can occur. Therefore the main limitation of hy-
perventilation is its short therapeutic duration.
CSF drainage
CSF drainage is an effective method of lowering ICP in pa-
tients who have an intraventricular catheter to monitor ICP
[31]. This is achieved by drainage of small amounts of CSF
for short periods of time in response to elevations in the ICP.
The main risks associated with ventriculostomy are infection
and haemorrhage, with the incidence of bacterial meningitis
varying between 6 % and 22 % [54, 55, 56].
Barbiturate coma
The use of barbiturates to induce a coma state is only suitable
for refractory raised ICP. Barbiturates work by reducing the
cerebral metabolic activity and thus reduce cerebral blood
flow. However there are several potential side effects of this
therapy including hypotension [57, 58]. Therefore careful
monitoring of the patient’s haemodynamic state is vital.
Surgery
The role of decompressive craniotomy in the presence of a
compressive pathology (such as subdural haematoma) is well
documented. However its role in the absence of a compressive
pathology is less well documented.
A number of studies, including the International Surgical
Trial in Intracerebral Haemorrhage (STICH) trial, showed no
real benefit in treating supra-tentorial ICH with craniotomy.
Of those whowere treated, a higher GlasgowComa Scale (≥9)
and a clot within 1 cm of the surface were associated with a
29 % relative benefit in functional outcome when compared
with medical management [59–61]. Furthermore surgical in-
tervention can provide more effective management in certain
conditions such as diffuse, severe TBI and middle cerebral
artery infarction than medical management [62].
However these studies did not include patients where the
haemorrhage was located in the cerebellum. Further studies
that did look at cerebellar ICH provided the conclusion that
large cerebellar haemorrhages that either compress the brain
stem or obstruct the fourth ventricle should be surgically re-
moved as soon as possible [63, 64–69].
With regards to the timings of when surgery should be
performed, there is no clear guidance on this [70]. The most
supportive evidence is for operative removal within 12 h;
however this is not conclusive.
Furthermore, bifrontal decompressive craniectomy in post-
traumatic intracranial hypertension has been associated with
significant reductions in AMP and has increased the compen-
satory reserve and therefore led to an improvement in the
patient’s RAP index. [71] Although decompressive
craniectomy has been reported to be beneficial in a number
of conditions there is currently insufficient evidence to prove
that it has the potential to improve outcome, despite showing
benefits under certain conditions [72, 73].
The role of the RAP index and AMP in future clinical
management
ICP indices were introduced to help improve the diagnostic
value of ICP. One of the main reasons for using ICP indices in
patients with raised ICP is to allow clinicians to treat raised
ICP proactively rather than reactively. The RAP index has
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already been used as a descriptor of neurological deterioration
in TBI patients. However it has yet to be used to guide clinical
management. One of the main reasons the RAP index may not
be a suitable marker to guide clinical management is its sus-
ceptibility to baseline effect errors. Given the dynamic nature
of ICP in conjunction with the varying causes responsible for
baseline pressure effects, it is little surprise that the use of a
static value of ICP (the mean ICP) may not provide the most
accurate measure of true, global ICP. One appeal of using
AMP instead of the RAP index as a marker for guiding clinical
management in patients with raised ICP is the fact that the
AMP has been shown to be uninfluenced by baseline effect
errors. However one limitation of using AMP, and other
parameters of the ICP waveform, as a marker to guide clinical
management is the lack of appropriate tools to accurately an-
alyse the ICP waveform objectively. However more sophisti-
cated algorithms are making this less of a problem, such as the
MOCAIP (morphological clustering and analysis of continu-
ous intracranial pressure) method [19], which has shown high
accuracy in analysing several ICP waveform parameters [55].
It is clear from the literature to date that the use of either the
RAP index or the AMP as a marker to guide clinical manage-
ment has its limitations.
However given the complexity of ICP, and the heterogene-
ity of the intracranial conditions that it is affected by, it is
difficult to imagine that the RAP index or AMP alone will
Fig. 5 The relationship between the different intracranial
pathological categories and the ICP, cerebral function, RAP index
and AMP. Intracranial pathologies can be categorised into five main
areas. The large circles represent the initial/primary pathology, with the
arrows showing the potential secondary pathologies that can arise from
the corresponding initial/primary pathology. For example, trauma can
cause a direct increase in the ICP through the expansion of the cerebral
parenchyma; however trauma can also result in damage to blood vessels
with resulting haemorrhage, or a disturbance within CSF dynamics, e.g.,
expanding tissue resulting in blockage of the CSF drainage pathways or
an increased risk of infection, which could cause a rise in the ICP through
increased metabolic turnover. Note that the initial/primary pathology may
itself not cause a significant rise in ICP; however the resulting secondary
pathologies could be responsible for the rise in ICP, for example a
malignant tumour itself may not cause a rise in ICP; however if the
surrounding blood vessels rupture then it will be the resulting
haemorrhage that will cause the rise in ICP. The nature of the primary
pathology will determine what potential secondary pathologies could
arise. The dotted circumferential lines represent the interval at which
the RAP index and AMP would be most clinically useful. If changes in
the AMP and/or RAP index are detected through ICP monitoring before
the patient exhibits any signs/symptoms, then this could allow the
clinician to implement a change in management sooner and therefore
minimise irreversible damage to the brain tissue and subsequently
improve patient outcome
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allow the clinician to make an informed decision that will
optimise patient outcome, without other factors being in-
volved including patient history, examination findings, basic
neuro-imaging, haemodynamic and biochemical markers.
The interval between the onset of raised ICP and just prior
to the onset of cerebral damage is where ICP indices could
prove most beneficial (Fig. 5).
Conclusion
Raised ICP is in essence the result of cumulative molecular
interactions, which establish three-dimensional multi-variant
vectors within the intracranial cavity. This in turn generates
pressure gradients that are exacerbated by the rigidity of the
encompassing skull.
A sound understanding of this complexity of ICP and how
it is affected by intracranial conditions is essential to achieve
successful clinical outcome. In addition, as the intracranial
cavity is essentially a highly dynamic and organised collection
of cells and molecules, the use of mathematical and statistical
modelling as a tool to accurately quantify and interpret intra-
cranial dynamics is important.
The important role of minimising disturbances in ICP on a
patient’s clinical outcome is evident and several studies have
improved the ability to use certain ICP parameters to help
achieve this. However it remains unclear which of these pa-
rameters, specifically, is best in predicting clinical outcome.
Both the RAP index and AMP are currently used as markers
for certain intracranial physiological parameters; however nei-
ther have yet been used as a marker to guide clinical manage-
ment. Further studies into this potential role of the RAP index
and AMP, including current barriers, are warranted.
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Comments
Intracranial pressure is a fundamental signal informing about cerebral ho-
meostasis in the majority of acute and chronic neurological diseases. In
neurocritical care it should be interpreted in conjunction with other signals
as a part of multimodal brain monitoring. In hydrocephalus or idiopathic
intracranial hypertension, ICP is frequently interpreted alone, and additional
information may be derived from its pulse waveform, respiratory, compo-
sition of slow waves (more or less periodical frequencies slower than
0.05 Hz), pathological plateau or ‘hyperaemic’ elevations. The pulse wave-
form of ICP has a long list of great publications such as Avezaat and
Ejindhoven’s PhD thesis (1), Portnoy’s arterial pulse to ICP pulse transmis-
sion models (2) or the morphological description from the Los Angeles
group animated by Xiao Hu (3) and many others. The amplitude of the
ICP pulse (AMP) is an effect of pulsation of arterial blood inside compliant
cerebral arteries. AMP is roughly proportional to the magnitude of its
source (i.e. the amplitude of arterial blood pulsations) and a ratio of com-
partmental compliances of the cerebral arterial bed and cerebrospinal fluid
space. In individual cases the AMP usually increases when the mean ICP
increases (4), but only when changes in the mean ICP are not solely pro-
cured by changes of central venous pressure (like in a change of body
position, but also the Queckenstedt test) or the intracranial pressure-
volume curve is very flat (like after craniectomy). In turn, the RAP is a
mathematical index derived from changes in the ICP and AMP. As such, it
is secondary to the observed changes in the ICP and AMP. Because of the
proposed [and verified by so many neuroscientists (5)] linear-exponential
shape of the pressure-volume characteristic, it may inform us whether the
current working point is on the flat (or linear) part of the curve or exponen-
tial (non-linear). In the first case the RAP is close to 0 (signifying the
compensatory reserve is good) and in the second close to +1 (the compen-
satory reserve is exhausted). At very high ICPs, where the pressure-volume
curve deflects to the right (5) and decreases its slope (which denotes a
critical ICP above which the arterial bed starts to collapse, i.e. the critical
closing pressure reaches diastolic blood pressure), the RAP becomes
negative.
It is difficult to say which of the two descriptors, AMP or RAP, is more
useful. I am sure that both parameters should be analysed in conjunction.
High AMP is not always associated with RAP close to +1. And RAP around
0 is not always associated with low AMP. AMP says more about cerebro-
vascular phenomena associated with arterial blood transport, and RAP
characterises better pressure-volume compensatory reserve. Both may be
useful, but RAP cannot be evaluated without proper detection of AMP.
And AMP equal to 0 may mean that the patient died, his cerebrospinal
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compliance is abnormally high, or the ICP transducer is broken. References:
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